Kume K et al. – The findings suggest that telmisartan may have additional benefits and be useful for the treatment of elderly hypertensive patients with Alzheimer's disease (AD).Methods
- A total of 20 patients with probable AD and essential hypertension were randomly assigned to the telmisartan group (n=10, 40-80 mg daily) or the amlodipine group (n=10, 5-10 mg daily) for 6 months.
- The groups had a similar significant reduction in systolic and diastolic blood pressure after treatment.
- The telmisartan group did not show any changes in cognitive function test scores, while the amlodipine group showed significantly higher scores on the AD Assessment Scale-Cognitive Subscale (Japanese version).
- Analysis of covariance to analyze treatment effect revealed that the telmisartan group showed increased rCBF in the right supramarginal gyrus, superior parietal lobule, cuneus, and lingual gyrus compared with the amlodipine group, while the amlodipine group showed increased rCBF only in the right cingulate gyrus compared with the telmisartan group at 6 months.